Ligand Pharmaceuticals Incorporated
LGND
$193.03
-$2.07-1.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 117.27M | 4.85M | -42.45M | -31.09M | -7.17M |
| Total Depreciation and Amortization | 9.16M | 8.10M | 8.31M | 8.63M | 8.99M |
| Total Amortization of Deferred Charges | 926.00K | 537.00K | 707.00K | 743.00K | 707.00K |
| Total Other Non-Cash Items | -103.65M | 8.49M | 13.16M | 38.59M | 26.88M |
| Change in Net Operating Assets | -10.62M | -6.17M | -5.17M | 11.60M | 7.12M |
| Cash from Operations | 13.09M | 15.80M | -25.45M | 28.47M | 36.53M |
| Capital Expenditure | -15.00K | -214.00K | -214.00K | -712.00K | -596.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -353.43M | -10.45M | 5.11M | -37.91M | -45.91M |
| Cash from Investing | -353.45M | -10.67M | 4.89M | -38.62M | -46.51M |
| Total Debt Issued | 460.00M | -- | -- | -- | -- |
| Total Debt Repaid | -113.26M | -7.00K | -7.00K | -6.00K | -10.00K |
| Issuance of Common Stock | 25.74M | 8.24M | 4.22M | 56.48M | 55.43M |
| Repurchase of Common Stock | -15.22M | -145.00K | -8.89M | -1.94M | -125.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 52.38M | 6.91M | -71.00K | -34.15M | -210.00K |
| Cash from Financing | 409.65M | 15.00M | -4.75M | 20.39M | 55.08M |
| Foreign Exchange rate Adjustments | -400.00K | 2.29M | 1.06M | -1.55M | 377.00K |
| Miscellaneous Cash Flow Adjustments | 2.82M | -2.74M | -78.00K | -- | -- |
| Net Change in Cash | 71.71M | 19.68M | -24.32M | 8.69M | 45.48M |